<DOC>
	<DOCNO>NCT02711228</DOCNO>
	<brief_summary>The purpose study assess impact immunoglobulin treatment subcutaneous injection every 2 week ( biweekly ) cohort patient primary secondary immune deficiency . The full study consist safety , efficacy Quality Life ( QoL ) evaluation pharmacokinetic ( PK ) sub-study . The primary objective study determine tolerability safety biweekly IgPro20 injection regimen compare PK outcome weekly biweekly IgPro20 therapy . Patients receive and/or currently receive immunoglobulin G ( IgG ) intravenous ( IVIg ) , subcutaneous ( SCIg ) infusion eligible inclusion meet inclusion/exclusion criterion . The study consist two part . In Part 1 study enrol subject receive IgPro20 weekly either 12 week ( patient SCIg infusion prior study ) 24 week ( patient IVIg infusion prior study ) . Part 2 consist biweekly treatment IgPro20 52 week , group . Additionally , study subject meet inclusion criterion PK sub-study undergo PK sample collection 1 week 2 week study Parts 1 2 , respectively .</brief_summary>
	<brief_title>Study Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin ( IgPro20 , HizentraÂ® ) Weekly Biweekly Schedules</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Full study : Female male patient primary secondary immunodeficiency , age 5 64 year , receive steady state immunoglobulin G replacement therapy . Pharmacokinetic substudy : Female male patient primary immunodeficiency , age 12 64 year age , steadystate IgPro20 replacement therapy willing undergo pharmacokinetic sample collection weekly biweekly IgPro20 dosing regimen . Patients protein lose condition : lymphangiectasis , nephrosis , status post cardiothoracic surgery require drainage tube 48 hour , proteinlosing enteropathy . Concomitant treatment plasma blood product ( include IgGs IgPro20 [ Hizentra ] ) within 21 day study entry and/or study . Any condition treatment , opinion investigator , would interfere obtain valid result subject . Women childbearing potential positive pregnancy test . Active infection time screening .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>